End stage chronic liver disease - yesterday, today and tomorrow

Liver Cirrhosis: Causes, Diagnosis and Treatment

Volumn , Issue , 2011, Pages 59-82

  Nayak, N C ^a   Jain, Deepali ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862183984     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (84)

1. Duffin JM. Why does cirrhosis belong to Laennec? Cmaj. 1987;137(5):393-6.
2. Roguin A. Rene Theophile Hyacinthe Laennec (1781-1826): the man behind the stethoscope. Clin Med Res. 2006;4(3):230-5.
3. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol. 1978;31(5):395-414.
4. Gall EA. Posthepatitic, postnecrotic, and nutritional cirrhosis: a pathologic analysis. Am J Pathol. 1960;36:241-71.
5. Nayak N. Nutritional liver disease. In: RNM MacSween PA, PJ Scheue, ed. Pathology of the Liver. London: Churchill Livingstone; 1979:pp 221-31.
6. Popper H, Schaffner F. Nutritional hepatic injury. AMA Arch Intern Med. 1954;94(5):785-800.
7. Patrick C. Alcohol, Culture, and Society. Durham: Duke University Press; 1952.
8. Lieber CS, Jones DP, Decarli LM. Effects Of Prolonged Ethanol Intake: Production Of Fatty Liver Despite Adequate Diets. J Clin Invest. 1965;44:1009-21.
9. Bhuyan UN, Nayak NC, Deo MG, Ramalingaswami V. Effect of Dietary Protein on Carbon Tetrachloride-Induced Hepatic Fibrogenesis in Albino Rats. Lab Invest. 1965;14:184-90.
10. Bhuyan UN, Deo MG, Ramalingaswami V, Nayak NC. Fibroplasia in experimental protein deficiency: a study of fibroblastic growth and of collagen formation and resorption in the rat. J Pathol. 1972;108(3):191-7.
11. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol. 2010;105(1):14-32; quiz 3.
12. Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med. 1999;48(4):184-8.
13. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet, 1995;346(8981):987-90.
14. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut, 1997;41(6):845-50.
15. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis. 2004;24(3):217-32.
16. Day CP. Who gets alcoholic liver disease: nature or nurture? J R Coll Physicians Lond. 2000;34(6):557-62.
17. Day CP, Bassendine MF. Genetic predisposition to alcoholic liver disease. Gut, 1992;33(11):1444-7.
18. Becker U, Gronbaek M, Johansen D, Sorensen TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology, 2002;35(4):868-75.
19. Lu XL, Luo JY, Tao M, et al. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004;10(16):2423-6.
20. Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol. 1997;58(5):486-94.
21. Niemela O. Biomarkers in alcoholism. Clin Chim Acta, 2007;377(1-2):39-49.
22. Nyblom H, Berggren U, Balldin J, Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol, 2004;39(4):336-9.
23. Hall PD. Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl. 1994;2:303-13.
24. AD Burt BP, Linda D Ferrel, ed. MacSeween's Pathology of the Liver. 5th ed. London: Churchill Livingstone; 2006.
25. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis. 2005;9(1):37-53.
26. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33(2):68-71.
27. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology, 2006;49(5):450-65.
28. Vasdev N, Kakati AG, Saigal S, Nayak NC. Spectrum of histological features in non-alcoholic fatty liver disease. Natl Med J India, 2007;20(6):282-7.
29. Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis. 2004;24(3):233-47.
30. Grant BF. Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. J Stud Alcohol. 1997;58(4):365-71.
31. Umbricht-Schneiter A, Santora P, Moore RD. Alcohol abuse: comparison of two methods for assessing its prevalence and associated morbidity in hospitalized patients. Am J Med. 1991;91(2):110-8.
32. Afroudakis A. Alcoholic liver disease -An overview. Ann Gastroenterol. 2000;13(4):290-8.
33. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol. 2005;4(1):52-5.
34. Yoon YH YH. Liver cirrhosis mortality in the United States, 1970-2003. Bethesda, MD: National Institue on Alcohol Abuse and Alcoholism; 2006. Report No.: 75.
35. Cochrane J, Chen H, Conigrave KM, Hao W. Alcohol use in China. Alcohol Alcohol, 2003;38(6):537-42.
36. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol. 2010;45(1):86-94.
37. Blumberg BS, London WT. Hepatitis B virus and the prevention of primary hepatocellular carcinoma. N Engl J Med. 1981;304(13):782-4.
38. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer, 1988;61(10):1942-56.
39. Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in North India. J Med Virol. 1987;21(2):137-45.
40. Nayak NC, Dhar A, Sachdeva R, et al. Association of human hepatocellular carcinoma and cirrhosis with hepatitis B virus surface and core antigens in the liver. Int J Cancer, 1977;20(5):643-54.
41. Nayak NC, Sachdeva R. Localization of hepatitis B surface antigen in conventional paraffin sections of the liver. Comparison of immunofluorescence, immunoperoxidase, and orcein staining methods with regard to their specificity and reliability as antigen marker. Am J Pathol 1975;81(3):479-92.
42. Nayak NC, Sachdeva R, Dhar A, Seth HN. Demonstration of hepatitis B virus surface component in human hepatocellular cancer cells. Indian J Med Res 1979;69:161-7.
43. Thung SN, Gerber MA, Purcell RH, London WT, Mihalik KB, Popper H. Animal model of human disease. Chimpanzee carriers of hepatitis B virus. Chimpanzee hepatitis B carriers. Am J Pathol. 1981;105(3):328-32.
44. Popper H, Shih JW, Gerin JL, et al. Woodchuck hepatitis and hepatocellular carcinoma: correlation of histologic with virologic observations. Hepatology, 1981;1(2):91-8.
45. Nayak NC. Vaccine against hepatocellular carcinoma--prospects of a new era in cancer control. Indian J Med Res. 1983;78 Suppl:1-7.
46. Report of a WHO meeting. Prevention of Liver Cancer: WHO Technical Report Series No.691, Geneva; 1983.
47. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336(26):1855-9.
48. Da Villa G, Piccinino F, Scolastico C, Fusco M, Piccinino R, Sepe A. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Res Virol. 1998;149(5):263-70.
49. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16(7):453-63.
50. Sathar SA, Sarkar C, Nayak NC. The changing scenario of hepatitis B and hepatitis C virus associated chronic liver disease -A histopathological analysis. Med Principles Pract. 1996;5:76-85].
51. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006;28:112-25.
52. Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol. 2010;41(3):425-30.
53. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118-29.
54. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82(8):967-75.
55. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
56. Nayak NC. Hepatocellular carcinoma--a model of human cancer: clinico-pathological features, etiology and pathogenesis. Indian J Pathol Microbiol. 2003;46(1):1-16.
57. Panda SK, Datta R, Gupta A, et al. Etiologic spectrum of acute sporadic viral hepatitis in children in India. Trop Gastroenterol. 1989;10(2):106-10.
58. Panda SK, Datta R, Kaur J, Zuckerman AJ, Nayak NC. Enterically transmitted non-A, non-B hepatitis: recovery of virus-like particles from an epidemic in south Delhi and transmission studies in rhesus monkeys. Hepatology, 1989;10(4):466-72.
59. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47-52.
60. Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol. 2007;42(7):513-21.
61. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132(4):296-305.
62. Nayak NC, Sathar SA. Chronic hepatitis -Are we zeroing in on it now? In: U.L. Wagholikar, K.P. Deodhar, eds. Recent advances in Pathology. 1st ed. New Delhi: Jaypee Publishers; 1998:126-49.
63. Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol. 2005;75(4):522-7.
64. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41.
65. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529-38.
66. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17 Suppl:S186-90.
67. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. Jama, 2003;289(22):3000-4.
68. Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezynska-Kurtycz J, Milkiewicz P. [Non-alcoholic fatty liver disease--new view]. Pol Merkur Lekarski 2008;24(144):568-71.
69. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009;49(1):306-17.
70. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234-8.
71. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol. 2002;33(11):1098-104.
72. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128(7):1898-906.
73. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications. Aliment Pharmacol Ther 2005;22 Suppl 2:48-51.
74. Stroffolini T, Cotticelli G, Medda E, et al. Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int 2010;30(6):867-70.
75. Nayak NC, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch Pathol. 1969;87(4):359-69.
76. Sama SK, Bhargava S, Nath NG, et al. Noncirrhotic portal fibrosis. Am J Med. 1971;51(2):160-9.
77. Saigal S NN, Jain D, Kumaran V, Mohanka R, etal. NCPF related end stage liver disease in adults -An evaluation from a study on living donor liver transplant recipients. Hepatol Int. In press.
78. Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis. 2002;22(1):59-72.
79. Sarin SK, Kumar A, Chawla YK, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007;1(3):398-413.
80. Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am J Surg Pathol. 2007;31(4):607-14.
81. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;11(6):627-34; discussion 10-1.
82. Nayak NC, Ramalingaswami V. Indian childhood cirrhosis. Clin Gastroenterol. 1975;4(2):333-49.
83. Sriramachari S, Nayak NC. Indian childhood cirrhosis: several dilemmas resolved. Indian J Med Res. 2008;128(2):93-6.
84. Scheinberg IH, Sternlieb I. Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr. 1996;63(5):842S-5S.